Press release, Helsinki, 19 November 2024 at 3 PM (EET) 

New German Customer Orders Nexstim NBS System 5

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new neurosurgery customer in Germany.

The Nexstim Navigated Brain Stimulation (NBS) System 5 ordered includes motor mapping, speech mapping and therapy modules. The NBS System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The information gained from the mapping may be used in pre-procedural planning. The therapy module allows the system to be used for the treatment of major depression and chronic neuropathic pain as CE-marked in Europe.

Mikko Karvinen, CEO of Nexstim, comments: “Our neurosurgery customers in Germany compose an extensive user community. As part of our strong presence in Germany, we have for over a decade now supported the International Symposium on nTMS in Neurosurgery and Neuromodulation held in Berlin. This year the event was organized by the neurosurgery departments of Charité Berlin, Heidelberg University Hospital and the Technical University of Munich. The symposium once again attracted a wide audience, fostering collaboration in clinical and research applications not only in Germany but within nTMS users internationally.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com